Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027
Point-of-care biosensors have been a commercial success in the area of diabetes management (glucose testing). Medical biosensors can also be used to diagnose cardiovascular issues, infectious diseases and cancer. Biosensor technologies are moving to point-of-care, getting closer to patients and disrupting the conventional diagnostic market. In particular, DNA-based diagnostic (akamolecular diagnostics) will become a key driver for growth. Point-of-care biosensors will become a $33 billion market by 2027.